Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17536154 | 0.98 | KDM4E (0.42) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL18713921 | 0.91 | KEAP1 (0.44) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL3870844 | 0.88 | KEAP1 (0.45) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL19866316 | 0.86 | TP53 (0.41) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL5872835 | 0.83 | KDM4E (0.52) | KDM4EASPHKDM8TTRKEAP1 | |
| SCHEMBL7941319 | 0.83 | TTR (0.41) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL7082885 | 0.81 | KEAP1 (0.44) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL15543847 | 0.81 | TTR (0.40) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL10193922 | 0.81 | LCK (0.44) | KDM4EASPHKDM8TP53TTR | |
| SCHEMBL3321387 | 0.81 | KEAP1 (0.50) | KDM4EASPHKDM8TP53TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106008195-A | Preparation method of 2,4-difluoro-5-iodobenzoic acid | 绍兴文理学院 | 2016-10-12 | — | — | CN | claimed |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-3281939-B1 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4059923-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | SHIONOGI & CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005113508-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113509-A1 | NOVEL 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-0721441-B1 | HALOGENATION REACTIONS | F2 CHEMICALS LTD (GB) | 2001-04-04 | — | — | EP | disclosed |
| US-5734073-A | Halogenation reactions | BNFL FLUOROCHEMICALS LTD (GB) | 1998-03-31 | — | — | US | disclosed |
| WO-1996003356-A1 | HALOGENATION REACTIONS | BNFL FLUOROCHEMICALS LTD. (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288326-A1 | Combination therapy | TYMP, TPMT, PNP | KDM4E 388/4885ASPH 887/4885KDM8 206/4885 |
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | KDM4E 253/4885ASPH 2160/4885KDM8 1602/4885 |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | KDM4E 131/4885ASPH 3948/4885KDM8 3435/4885 |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | KDM4E 269/4885ASPH 4227/4885KDM8 3781/4885 |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, PIP4K2B, IMPDH2 | KDM4E 188/4885ASPH 2473/4885KDM8 1318/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | KDM4E 92/4885ASPH 1464/4885KDM8 375/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | KDM4E 187/4885ASPH 932/4885KDM8 387/4885 |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | KCNQ2, RCC1, SFPQ | KDM4E 248/4885ASPH 4109/4885KDM8 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.